20362
Agents demonstrating utility in Phase III clinical trials , including eribulin , ixabepilone , cabazitaxel and trastuzumab - DM1 will be highlighted , as well as novel agents currently in development and future directions for MTAs .
 Chemical: eribulin; Chemical: ixabepilone; Chemical: cabazitaxel; Chemical: DM1
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 Chemical: eribulin; Chemical: ixabepilone; Chemical: cabazitaxel; Chemical: DM1